Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

Columbia University Medical Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Columbia University Medical Center
Drugs:Journal:Link
Date:Jul 2015

Description:

Patients:
This phase 2 study involved 29 recurrent glioblastoma patients who had been previously treated with surgery, radiation, and temozolomide chemotherapy. The median patient age was 54 years and 59% were male.

Treatment:
Patients received biologic therapy with dasatinib, which is a tyrosine kinase inhibitor.

Toxicities:
The most severe toxicity was grade 4 confusion. Grade 3 fatigue, anorexia, and lymphopenia were also reported.

Results:
The median overall survival was 8.9 months.

Support:
This study was partially supported by Bristol Myers Squibb.

Correspondence: Dr. Andrew B. Lassman; email: [email protected]



Back